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CASE REPORT
Secundum atrial septal defect (ASD) occurs in 3.78
per 10,000 live births.1 Surgical repair is a well es-
tablished procedure with a low mortality rate.2
Since its first introduction in 1976,3 however,
percutaneous closure of secundum ASD with an
Amplatzer septal occluder (ASO) has gained wide
acceptance as an effective alternative to open-heart
surgery.2–5 The major advantage of transcatheter
closure is that it avoids a median sternotomy and
cardiopulmonary bypass. In addition, the compli-
cation rate with the ASO, although not negligible,
is lower than with surgery.2,5,6 Reported com-
plications include arrhythmias, thrombus, embo-
lization, pericardial effusion, cardiac perforation
with tamponade, transient ischemic attack, cere-
bral embolism, and sudden death.7–10 The 2%
incidence of arrhythmia after ASO implantation is
considerably lower than the 30% incidence re-
ported after surgical closure.2 Electrocardiographic
abnormalities reported after transcatheter closure
are usually asymptomatic11 and have included
premature atrial contraction, atrial flutter, atrial
fibrillation, supraventricular tachycardia, ST elev-
ation, and atrioventricular (AV) block.3 Complete
AV block (CAVB) is reported to occur in 0.35–
2.5% of cases and is usually benign and tran-
sient.1,6,8,10,11 We report a patient who had CAVB
for 24 days following ASO implantation.
Case Report
A 9-year-old boy was incidentally found to have
ASD. He did not complain of fatigue or dyspnea.
He was 123 cm tall and weighed 21 kg. On aus-
cultation of the heart, there was a widely fixed split
S2 and a grade 2/6 systolic ejection murmur at the
left mid-sternal border. The patient did not have
a bulging or hyperdynamic precordium, nor was
there a right ventricular heave. Chest X-ray showed
a dilated right atrium without increased pul-
monary vascularity. Electrocardiography showed
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Amplatzer Septal Occluder-induced 
Transient Complete Atrioventricular Block
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Percutaneous transcatheter atrial septal defect (ASD) closure is a widely used technique that has replaced
open-heart surgical closure in many centers.  The most common implant is the Amplatzer septal occluder
which seems to be a highly effective and safe device. However, there are reports of complications associated
with its implantation. We report a 9-year-old boy who presented with complete atrioventricular block after
undergoing percutaneous closure of a large secundum ASD with an Amplatzer septal occluder. We treated
the patient with oral prednisolone. The patient’s atrioventricular conduction improved to second-degree
Mobitz type 1 block on post-procedure day 24 and first-degree block on day 35. We conclude that patients
with Amplatzer septal occluder-induced complete atrioventricular block generally have a good outcome,
although it may take several weeks for improvement. [J Formos Med Assoc 2007;106(12):1052–1056]
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a normal sinus rhythm with incomplete right
bundle branch block. Transthoracic echocardiog-
raphy showed a 2.74-cm secundum ASD and 
a bicuspid aortic valve. Left ventricular systolic
function was borderline normal (ejection fraction,
0.53), and the right atrium, right ventricle, and
main pulmonary artery were dilated. There was
also mild pulmonary stenosis and moderate tri-
cuspid regurgitation. Hemodynamic data obtained
during cardiac catheterization revealed a step-up
of O2 saturation in the right atrium (91%) and
main pulmonary artery (91%) compared to the
superior (72%) and inferior (79%) vena cavae.
Pulmonary arterial pressure was normal. The ratio
of pulmonary to systemic blood flow (Qp/Qs)
was 3.5. Contrast medium injected into the right
upper pulmonary vein in the four-chamber view
showed a large secundum ASD.
With consent from the patient’s parents, we
performed transesophageal echocardiography and
implanted an ASO under general anesthesia with
endotracheal intubation. The ASD had a limited
anteroinferior rim (Figure 1A) and a deficient 
superoanterior rim, measuring 23 mm by echo-
cardiography and 25 mm by Amplatzer balloon 
sizing. We therefore chose to implant a 28-mm
ASO (AGA Medical Corp, Golden Valley, MN,
USA), which was deployed under fluoroscopic
and echocardiographic guidance. The left atrial
disc was deployed in the left atrium and the waist
in the defect itself. The right atrial disc was then
deployed in the right atrium. Although the ASO,
with the delivery cable still in place, was seen 
to be in the proper position, the electrocardio-
gram showed CAVB with an accelerated junc-
tional rhythm of 80 bpm. We therefore retrieved
the ASO, and the normal sinus rhythm returned.
However, CAVB recurred after redeployment of
the device. Although the right atrial disc of the
ASO was seen to be touching the septal annulus
of the tricuspid valve after occlusion, there was
no significant tricuspid valve stenosis or insuf-
ficiency present (Figure 1B). We thought that 
a slightly smaller device (26-mm ASO) might be
insufficient to close the ASD. In addition, the 
patient’s junctional escape rhythm was around
75 bpm (Figure 2) and his CAVB might be tran-
sient, as has usually been reported. Therefore, we
released the ASO.
After the procedure, however, he continued to
have CAVB, which was initially associated with
mild hypotension. Dopamine was therefore ad-
ministered for the first 2 days. We thought the
CAVB might have resulted from tissue edema and
began oral prednisolone 40 hours after ASO im-
plantation, starting with a dose of 1.4 mg/kg/day
for 20 days, then tapered to 0.25 mg/kg/day for 








Figure 1. (A) Transesophageal echocardiography before Amplatzer septal occluder (ASO) implantation: apical four-chamber view shows a
large secundum atrial septal defect with a limited anteroinferior rim measuring approximately 2 mm in length. (B) Although the right atrial
disc of the ASO was seen touching the septal annulus of the tricuspid valve after occlusion, there was no significant tricuspid valve stenosis
or insufficiency present. LA = left atrium; ASD = atrial septal defect; AI = anteroinferior rim; RA = right atrium; TV = tricuspid valve; Ant. =
anterior; Sep. = septal.
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given aspirin, 100 mg once daily. He had no chest
tightness or dyspnea at any time after the proce-
dure. A 24-hour Holter study 4 days after the pro-
cedure showed CAVB with a mean junctional
escape rate of 57 bpm (atrial rate, 93–136 bpm).
After discharge, the patient had serial electro-
cardiograms that showed gradual improvement
in his AV conduction. On post-procedure day 
24, he had Mobitz type I (Wenckebach) AV block
(Figure 3) and on day 35, first-degree AV block with
incomplete right bundle branch block (Figure 4).
A 24-hour Holter study 6 months after the 
procedure showed recovery of sinus rhythm with
first-degree AV block. Twelve months after the
procedure, he still had first-degree AV block.
Discussion
In most reports, the CAVB following ASO im-
plantation has resolved within 3 days. The longest
previously reported duration of block was about
2 weeks. Our patient had CAVB for about 24 days,
after which the block gradually improved over the
next several months.
Precise measurement of the ASD so as to avoid
placing an oversized device is important to mini-
mize the risk of CAVB. In our patient, the balloon
stretch diameter of the ASD was 25 mm, so we
chose a 28-mm ASO to maximize the chance of
ASD closure. Du et al recommended choosing an
ASO equal in size or up to 2 mm larger than the
balloon stretch diameter.12 However, if the bal-
loon stretch diameter is greater than 25 mm, an
ASO 2–4 mm larger than the diameter has been re-
ported to produce closure rates equivalent to those
for smaller ASD occluded by a proportionately
smaller ASO.10 Chessa et al reported a patient with
CAVB after implantation of an 18-mm ASO, with
reversion to sinus rhythm when the ASO was 
replaced with a 14-mm device.1 In a series of 
197 patients reported by Wang and colleagues,
only one patient developed CAVB for 3 days after
ASO implantation. They used devices equal or














Figure 2. Electrocardiogram after the second deployment of the Amplatzer septal occluder shows atrioventricular 
dissociation with an atrial rate of 100 bpm and a ventricular rate of 75 bpm.
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There may be factors other than just ASO size
that are involved in the development of AV block.
Suda et al reported that the device size, device/
height ratio, and Qp/Qs were all significantly
greater in patients who developed post-procedure
AV block of any degree. In their study, patients with
devices larger than 19 mm and a device/height
ratio greater than 0.18 were at a higher risk of
having procedure-associated CAVB.4 Our patient
had a high Qp/Qs and a device/height ratio of
0.22, which, by the results of Suda’s group, put
him at risk of developing AV block.
If second- or third-degree AV block does not
spontaneously convert to 1:1 AV conduction within
30 minutes following implantation, it has been
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Figure 4. Electrocardiogram on post-procedure day 35 shows first-degree atrioventricular block, incomplete right 
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Figure 3. Electrocardiogram on post-procedure day 24 shows Mobitz type I (Wenckebach) atrioventricular block.
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with a smaller ASO.1,9 Our patient’s CAVB resolved
when we temporarily retrieved the device but re-
curred when it was reimplanted. However, he had
a junctional escape rhythm with an adequate rate
and we assumed that the CAVB would soon revert
to normal. We therefore chose to leave the 28-mm
ASO in place.
The mechanism causing conduction defects
and rhythm disturbance after ASO implantation
is unclear, although it is reasonable to hypothe-
size that it relates to the close proximity of the
device to the AV node. A large ASO might com-
press the AV node, producing edema and inflam-
mation of the adjacent cardiac tissue secondary
to friction from the atrial discs. Assessment of
the real spatial relationship between the atrial
discs and the AV node by other methods, such as
three-dimensional echocardiography, may yield
more insight on this issue.4
There are no controlled studies supporting the
use of corticosteroids to enhance AV node recovery
after ASO implantation, so the treatment is em-
piric. High-dose intravenous steroids (2 mg/kg/
day) followed by oral steroids for 3 weeks have
been used empirically with apparently good re-
sults for AV block after transcatheter closure of 
a perimembranous ventricular septal defect.13 In
theory, high-dose steroid (2 mg/kg/day) and as-
pirin (100 mg/kg/day in 3 divided doses) ought
to be effective in reducing inflammation and
thereby normalizing conduction.14 Our patient’s
response was not as rapid or complete as that in
the aforementioned reports. His final outcome
with only first-degree AV block, however, was
good despite the time it took for improvement.
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